SEPT9 Test: Completed pivotal trial enrollment

Epigenomics completed enrollment of 7,852 patients in the U.S. and German pivotal PRESEPT trial. The company has non-exclusive licensing arrangements in place for use of the Septin 9 biomarker with A...